NaNotics to collaborate with Mayo Clinic on nanomedicine cancer treatment

Latest articles

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

NURO embarks on funding round for neurotech communication system

World’s first multimodal neurotech operating system from NURO allows you to communicate using just your brain. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

It’s time to reboot longevity and healthy aging

Dr Michael Roizen calls for fundamental societal changes to ensure the benefits of longevity and healthy aging are realised. Later this year, best-selling author Michael...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

“World’s first” cultural-matching app for care sector launches

Care receivers can be paired with carer based on religious understanding and culture thanks to AI tech developed during pandemic. A graduate has created what...

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

NURO embarks on funding round for neurotech communication system

World’s first multimodal neurotech operating system from NURO allows you to communicate using just your brain. DISCLOSURE: Longevity.Technology (a brand of First Longevity Limited) has...

Click the globe for translations.

Small but mighty – new cancer treatment could generate improved outcomes for millions of cancer patients.

NaNotics LLC, a nanomedical company focused on developing and commercialising NaNots™, a novel subtractive nanoparticle that treats disease by capturing and clearing pathogenic molecules from blood, today announced a research collaboration with the Mayo Clinic to develop a NaNot that targets the soluble form of PD-L1, a tumour-generated immune inhibitor. The goal is to file an investigational new drug (IND) application with the US Food and Drug Administration (FDA) and commence human trials within two years.

Longevity.Technology: Cancer cells with high levels of PD-L1 are able to “trick” the immune system into not attacking, allowing tumours to become more advanced. Approved drugs against PD-L1 do exist today, but are limited in their capabilities. Specifically, they are unable to distinguish pathogenic soluble PD-L1 from membrane PD-L1 – which also has a vital immune regulatory role – and this leads to dose-limiting toxicity. Soluble PD-L1 – also known as “sPD-L1” – is elevated in many cancer patients and correlates very negatively with survival.

NaNots are distinct from drug therapies in that they deplete soluble targets without engaging membrane forms of the same target, something that drugs generally cannot do. Furthermore, NaNots offer ultra-low toxicity in comparison with drug therapies. Multiple animal studies to date have shown no measurable NaNot toxicity – even at 25-100 times the planned dose in humans.

Sean Park, MD, PhD, oncologist at MayoClinic, said: “Our team has been studying sPD-L1 for several years. We believe it’s a key driver of immune evasion for many tumor types. The ability to deplete sPD-L1 without incurring the toxicity of drugs against PD-L1 is potentially significant. We’re excited to collaborate with NaNotics and test NaNots against sPD-L1 in humans for the first time.”

“Collaborating with Dr Park and his team at Mayo Clinic is a dream come true for us,” said Lou Hawthorne, CEO of NaNotics and the inventor of NaNots – the subject of 12 granted patents to date. “Not only are they world-class scientists with extensive human trial experience, but they also possess deep knowledge of sPD-L1 specifically.

Nanotics are seeking further Series B funding to advance their revolutionary NaNot treatment of a host of chronic and acute conditions.
Lou Hawthorne, CEO of NaNotics

“Dr Park’s team includes Haidong Dong, MD, PhD, co-discoverer of PD-L1. All they need is a way to deplete the target, which we’re happy to provide with our platform. Together, we have an opportunity to explore a fundamentally new kind of treatment that could contribute to improved outcomes for millions of cancer patients.”

As part of the collaboration, NaNotics will provide its core nano-depletion platform and Mayo Clinic will provide an antibody of its own design against PD-L1, which will be specific to sPD-L1 once incorporated into a NaNot. Mayo Clinic will also provide a transgenic mouse model that secretes human sPD-L1, as well as a broad range of know-how. Mayo Clinic and Drs Sean Park and Haidong Dong have a financial interest in NaNots™ targeting sPD-L1. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Sugar-proof your health with the GLYLO weight loss and antiaging supplement

Move your New Year's resolution up a gear with GLYLO, a double-action supplement that can increase weight loss while also slowing aging. Choosing an effective...

Related articles

Biotech LyGenesis expands its liver regeneration tech

A new peer-reviewed paper demonstrates the success of using fat-associated lymphoid clusters as expandable niches for ectopic liver regeneration. LyGenesis, a clinical-stage biotech developing cell...

Mental illness drug discovery company Neurai Life Sciences launches

AI will drive discovery of innovative small molecules and next generation therapies to treat mental health disorders. Wuhan, a bioceutical company focused on alternative plant-based...

StarkAge secures 2 million euros for senescence targeting therapy

Funding from Bpifrance's Deeptech program will drive development of company’s immunotherapy approach targeting cellular senescence in age-related disease. French biotech startup StarkAge Therapeutics today announced...

Genflow IPO “starts a new chapter” for longevity biotech

Company floats on London Stock Exchange and becomes Europe’s first publicly traded longevity biotech. Today, Genflow Biosciences became the first longevity biotech IPO of 2022...

Roll up, roll up… it’s the Longevity Biotech Virtual Job Fair!

Amplifying the longevity biotech space with exciting opportunities and brand-new start. The new year brings new opportunities, and the new Longevity Biotech Virtual Job Fair...

    Subscribe to our newsletter